Category Archives: Cardiology

UNC Hospitals Performs First Transcatheter Tricuspid Valve Replacement in North Carolina | Newsroom – UNC Health and UNC School of Medicine

April 7, 2024 medical

John P. Vavalle, MD, MHS, FACC, and Matthew A. Cavender, MD, MPH, FACC, interventional cardiologists and their collaborative team in the Structural Heart Disease Program at UNC, have performed their first transcatheter tricuspid valve replacement in the clinical setting, a revolutionary treatment for patients living with a common type of heart valve disease.

CHAPEL HILL, N.C. For the first time in the state of North Carolina,thestructural heart teamatUNC Hospitalshasperformedatranscatheter tricuspid valve replacementin the clinical setting.Theimplant, whichwas only the 12th in the UnitedStates,is arevolutionarytreatmentfor patientslivingwithtricuspid valve regurgitation (TR), acommontype of heartvalve disease.

We now have apercutaneous,minimally invasive way to fix tricuspid valve regurgitation and offer valve replacement withoutthe need foropen heart surgery, saidJohn Vavalle, MD, MHS, FACC, medical director of theStructural Heart Disease Program at UNC Hospitals and associate professor of medicine at the UNC School of Medicine. Its only at a place like UNC, where there is this spirit of collaboration and this desire to push the technology forward, that you can do this kind of work.

About 5 in 1,000 people in the United States have severe tricuspid valve regurgitation.The condition occurs when thetricuspid valve,the valve that separates the right atrium and the right ventricleof the heart, does not close properly. As a result, blood cannot be ejected to the lungs to be oxygenated and instead flows back into the body.

Without treatment,the condition can become life threatening.It can cause fluid buildup in the abdomen and legs and weakening of theheart muscle, resulting infatigue, low energy, breathlessness, andevenkidney failure.Medicines like diuretics can help improve swelling from the fluid buildup, but fixing a leaky valve previously required open heart surgery.

Many of these patients are too sickto have major open-heart surgery, including our very first patient, said Vavalle. This procedure is much more minimally invasive.Its done through catheters and over wires inserted through the blood vessels in the groin,allowingus to implantanewtricuspidvalve in place of the old one.

The EVOQUE tricuspid valve replacement system, created by the Edwards Lifesciences Corporation, is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation.

The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TRdespite optimal medical therapy, for whom tricuspid valve replacement is deemed appropriate by a heart team.

TheUNC Heart Valve Clinic, which is an American College of Cardiology certified Transcatheter ValveCenter of Excellence, was one of20centers in the United Statesselected for implanting thevalvebecause of UNCshigh level of expertise.It is the only center in the state of North Carolina currently performing this procedure.

The same team, led by Vavalle and Thomas Caranasos, MD, as co-principal investigatorsparticipated intheTRISCEND II clinical trialthat determined the safety and effectiveness of the EVOQUE valve,eventually leadingto FDA approval.

The surgery requires a diverse team of cardiologists, cardiac surgeons, cardiac anesthesiologists, and advanced imagers. John Vavalle worked with fellow interventional cardiologistMatthew Cavender, MD, MPH, chief of cardiac surgeryJohnIkonomidis, MD, PhD, anesthesiologistEmily Teeter, MD, FASE, and imaging specialistThelsa Thomas Weickert, MD, on the case.

Media contact:Kendall Daniels, Communications Specialist, UNC Health | UNC School of Medicine

Cardiawave is Presenting the 30-day Follow-up Results from its Valvosoft Pivotal Study on the Teatment of Severe … – Diagnostic and Interventional…

April 7, 2024 medical

April 5, 2024 Cardiawave SA, a French medtech company that has developed an innovativeNon-Invasive focused Ultrasound Therapy(NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rdannual conference of the American College of Cardiology in Atlanta, Georgia. This is a leading event in the cardiovascular medicine calendar, which brings together specialists from around the world to discuss the latest advances, research results and clinical innovations in the field of cardiology.

Prof. Eric Van Belle, cardiologist at Lille University Hospital, one of the principal investigators for the European pivotal study, commented: Im very proud to present the excellent results obtained using Cardiawaves NIUT device to treat patients with severe symptomatic aortic valve stenosis, leading to a significant improvement in their condition and a better quality of life.This ACC.24 presentation represents a major contribution to the advance of science and will open up innovative therapeutic strategies for cardiology patients.

A summary of the poster session will be published on theJournal of the American College of Cardiologys website.

Presentation title:QUALITY OF LIFE ASSESSMENT AT 30-DAYS FOLLOW-UP OF THEVALVOSOFTPIVOTAL STUDY ON SEVERE AORTIC VALVE STENOSE PATIENTS" (control number 16930)

Time and date: April 8, 2024 -9:32 a.m.9:42 a.m. EDT

The results of the Cardiawave First-in-Human Valvosoft FIM Study were published in The Lancetin November 2023: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01518-0/fulltext

For more information:www.cardiawave.com

Find more ACC24 conference coverage here

See the rest here:

Cardiawave is Presenting the 30-day Follow-up Results from its Valvosoft Pivotal Study on the Teatment of Severe ... - Diagnostic and Interventional...

Cardiology

Real-world Evidence at the American College of Cardiology Scientific Session ACC.24 to Demonstrate Positive Impact … – Diagnostic and Interventional…

April 7, 2024 medical

April 4, 2024 Viz.ai, a leader inAI-powereddisease detection and intelligent care coordination, announced new clinical data supporting advancements in cardiology care. Three studies, to be presented at theAmerican College of Cardiologys (ACC) Annual Scientific Session & Expo 2024, have shown positive outcomes with real-world impact ofViz.aiin clinical practice for patients with hypertrophic cardiomyopathy (HCM), a commonly inherited heart disease that often goes undetected. TheViz HCMmodule is the first and only AI algorithm cleared by the FDA for HCM.

AtViz.ai, we invest in our algorithms to ensure the technology reliably detects suspected conditions, including HCM, and improves patient care and outcomes, said Molly Madziva Taitt, Ph.D., VP of Global Clinical Affairs atViz.ai. We are pleased that the clinical evidence accepted at the ACC shows the Viz HCM modules consistent performance across different phenotypes and patient backgrounds, demonstrating its potential to be used as an effective, pragmatic method to triage patients for clinical review.

The first study, titled Detection of Hypertrophic Cardiomyopathy on Electrocardiogram using Artificial Intelligence, evaluated the performance of the Viz HCM algorithm across racial backgrounds at Mass General Hospital, Brigham and Womens Hospital and Salem Hospital. The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.

These findings demonstrate that the Viz HCM algorithm can help to identify patients with HCM using easily accessible ECG equipment, said Carolyn Ho, MD, Medical Director of the Cardiovascular Genetics Center at Brigham and Womens Hospital and Associate Professor of Medicine at Harvard Medical School. The Viz HCM performance was consistent across different racial backgrounds, so use is likely to be generalizable to different settings.

The second study, Racial and Phenotypic Variations in Detection of Hypertrophic Cardiomyopathy using an Artificial Intelligence-Enabled Electrocardiogram: Real World Experience, assessed the performance of Viz HCM across specific phenotypes, including obstructive and apical HCM, and various racial backgrounds at Morristown. The retrospective analysis found that across 1,463 patients, the model performed well in Caucasian and African American races with 66.8% and 72.5% sensitivity, respectively, suggesting its potential for early detection. Notably, in patients with apical HCM, the model performed particularly well with 89.3% sensitivity.

This study further demonstrates the screening capabilities of AI with a common, non-invasive electrocardiogram, and in particular the Viz HCM algorithm, to detect HCM, especially for certain phenotypes such as apical HCM, said Matthew Martinez, MD, Director of Sports Cardiology and HCM at Atlantic Health System.

The third study, Probability Score Sorting from an ECG Deep Learning HCM Algorithm: Insights from the Prospective HCM Pilot Trial evaluated the efficacy of a sorting feature in enhancing positive predictive value (PPV) for disease detection compared to chronological sorting at Mt. Sinai. Results showed that sorting by probability scores increased PPV from 20% to 70% for the top 10 results and from 20% to 80% for the top five results of HCM-suspected cases. This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.

These data suggest that a sorting mechanism using probabilistic model outputs is an effective and pragmatic method to triage patients for clinical review who are deemed to have suspected HCM by deep learning algorithms applied to the electrocardiogram, said Joshua Lampert, MD, FACC, Assistant Professor of Medicine and Medical Director of Machine Learning for Mount Sinai Fuster Heart Hospital, We also demonstrated prospectively that well-calibrated model probabilistic outputs reflect the actual likelihood of disease in clinical practice. This information can be valuable for clinicians particularly when it comes to counseling patients, though clinicians should make clinical decisions based on prespecified binary classification thresholds.

For more information:www.viz.ai

Find more ACC24 conference coverage here

Real-world Evidence at the American College of Cardiology Scientific Session ACC.24 to Demonstrate Positive Impact ... - Diagnostic and Interventional...

Cardiology

American College of Cardiology Sets Full Range of Education Sessions and Meetings ACC Scientific Session, ACC.24 – Diagnostic and Interventional…

April 7, 2024 medical

April 3, 2024 In gearing up for its Annual Scientific Session, ACC.24, amidst the 75th anniversary of the organization, the American College of Cardiology (ACC)has planned a full range ofeducational programming, special events and peer networking scheduled throughout the April 6-8 eventin Atlanta, GA.Here is an overview of sessions, events and meetings coordinated to help members in particular specialties, sections and areas of interest learn and engage with peers and expert cardiology professionals to advance their practice, patient care and careers.

Symposiums at ACC

The Symposiums at ACC.24 offer consecutive sessions which provide attendees with the opportunity to focus on a specific area of interest. Cardiovascular Update for the Clinician: A Symposium by Valentin Fuster will offer the latest advances in the treatment of cardiovascular disease and ways to integrate them into daily practice. The Pharmacology Program will cover hot topics in cardiovascular medicine that are key issues that pharmacists, as well as other health care team members, face in managing complex patients.

Intensive Sessions

Offering what ACC refers to as an opportunity for attendees to deep dive into specific areas of concentration, the Intensive Sessions focus on new and growing areas in cardiovascular practice, and use gaps in competencies and knowledge to develop sessions that will expand an attendee's understanding of the selected topic. ACC reports that this year's Intensive Session is a four-part series on the Business of Cardiology led by co-chairs Alison Bailey, MD, FACC and Tyler J. Gluckman, MD, FACC. With 18 presentations led by business and cardiology experts in four key sessions with multiple expert presenters:

Core Knowledge in Action

The Core Knowledge in Action Series at ACC.24 is guided by prominent clinicians and leaders, and focuses on important fundamentals in managing and treating heart conditions. This includes a review of updated clinical guidelines and best practices. Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronary artery disease, and antiplatelet therapy after coronary stenting. Each session is interactive and includes knowledge check-ins and dedicated time for discussion.

When Statins Are Not Enough Non-statin Lipid Lowering Therapies (Session 801): this session will examine non-statin pharmacologic therapies (ezetimibe, PCSK9 inhibitors, inclisiran and bempedoic acid) to lower LDL and cardiovascular risk; and will offer practical knowledge on integrating non-statin therapies, including when and how to use them for optimal patient outcomes.

Heart Failure with Preserved Ejection Fraction: How to Find and Treat It (Session 802): ACCs planning team notes that this insightful session will delve into HFpEF covering topics such as diagnosis, evidence-based therapies, and the nuances of medical intervention. Learn practical insights in diagnosing HFpEF, when exercise hemodynamics play a crucial role and the cath lab may not be readily available, and gain a better understanding of effective treatment strategies.

Is Viability Still Viable and How Should We Assess It? (Session 803): The session will feature case-based examples showcasing the use of viability studies, offering real-world insights into their application and experts will navigate attendees through the spectrum of imaging modalities, from Q waves to MRI, and explore the nuances of echocardiography, SPECT, PET, and cardiac MRI for viability assessment.

Too Many Choices? When to Use What Modality for the Assessment of Coronary Artery Disease (Session 804): participants will be guided through the options in the assessment of coronary artery disease (CAD), providing a detailed exploration of CT, Echo, nuclear, and MRI in a comprehensive discussion with experts which will wrap up with an interactive Q&A session.

Antiplatelet Therapy After Coronary Stenting What You Need to Know (Session 805): Here, expert faculty will navigate the complex landscape of antiplatelet therapies with a specialized focus on post-percutaneous coronary intervention (PCI)

Additionally, ACC will be offering these Education Sessions:

The Personalized Skills & Simulation Center at ACC.24 offers a blended learning space where participants are immersed in a dynamic educational experience that offers asynchronous hands-on simulation stations across variety of CV disease states. In addition, a small stage seamlessly combines interactive lectures with hands-on learning stations.

ACC Guidelines Sessions allow participants to learn how to implement, optimize, and translate guidelines into clinical practice from key members of the guideline committees and experienced colleagues. Notably, 2024 marks the 40th Anniversary of ACC/AHA Guidelines.

In addition to its expansiveprogram, ACC reports that many meetings and events will be taking place throughout ACC.24 in and around the Georgia World Congress Center.

One special program note involves ACCs plans to encourage members to participate in its Annual Giving Day, Saturday, April 6, in support of the ACC Foundation. Members can visit the Bridge to the Future in Lounge & Learn to take a commemorative walk across the bridge, learn more and place your name on our donor wall. Donations (text ACC75 to 41444 to contribute) over $75 will receive a commemorative 75th anniversary gift, according to the organization, which noted that contributions of any size will support ACCs work to:

ACC has planned the following meetings and events throughout ACC.24, which include:

Friday, April 5

Program Directors & Graduate Medical Educators Symposium

ACPC Community Day

Diversity and Inclusion Town Hall and Reception

LGBTQ+ Networking Reception

Saturday, April 6

New CV Team Members Meet & Greet Breakfast

Women in Cardiology Section Meeting

Critical Care Cardiology Section Meet & Greet

Meet Your Fit Council

Early Career Section Networking

Geriatric Cardiology Section Meeting

Vascular Disease Section Meet & Greet

CV Team Hands-On Echo Training

Healthcare Innovation Section Reception

Fit Mix & Mingle

Women in Cardiology Networking Reception with Sandra J. Lews, MD, FACC, and Women as One

ACPC Section Meeting

CV Imaging Section Meeting & Reception

CV Team Section Meeting & Reception

Future of Cardiology Reception

Sunday, April 7

Meditation Session

Career Fair

Federal Section Lunch

Resident and Student Mentoring Event

Emerging Leaders Mentorship Program

Cardio-Oncology Section Meeting

Reproductive Health & Cardio-Obstetrics Section Meeting and Reception

Monday, April 8

Medical Resident Breakfast

Women in Cardiology Breakfast with The Council

Annual Convocation & 75th Anniversary Celebration

More information: http://www.acc.org

Follow DAIC coverage of ACC.24 news here.

ACC.24: Smidt Heart Institute Experts to Share Research Findings, Clinical Knowledge – Diagnostic and Interventional Cardiology

April 7, 2024 medical

April 6, 2024 Experts from theSmidt Heart Instituteat Cedars-Sinai will share new research and participate in more than 70 discussions during theAmerican College of Cardiology (ACC) Annual Scientific SessionApril 6-8 in Atlanta.

Throughout the conference, Smidt Heart Institute experts will be available for media interviews.

Smidt Heart Institute experts look forward to contributing their clinical and research expertise and learning from colleagues at this important meeting,saidEduardo Marbn, MD, PhD, executive director of the Smidt Heart Institute and the Mark S. Siegel Family Foundation Distinguished Professor.

During the awards ceremony at the Convocation and Reception, Monday, April 8, 4-6 p.m. EDT, the ACC will presentSumeet Chugh, MD, associate director of theSmidt Heart Institute, with this yearsDistinguished Scientist Award-Clinical Domain.

Chugh,the Pauline and Harold Price Chair in Cardiac Electrophysiology Research at Cedars-Sinai, investigates the causes of and potential treatments for abnormal heart rhythms, including sudden cardiac arrest.Chugh leadstwo ongoing studiesthat are collecting data from people who suffer sudden cardiac arrest in order to understand how to prevent this usually fatal condition.

The following experts also are available for interviews throughout ACC.24:

Christine M. Albert, MD, MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, will present several sessions, including Risk Stratifying ACM-Detected Ventricular Arrhythmias From PVCs to Sustained VT, Sunday, April 7, 3:30-4:30 p.m. EDT. She also will serve as a panelist on the Eugene Braunwald Keynote, Monday, April 8, 1:30-2 p.m. EDT, and she will co-chair electrophysiology research presentations.

C. Noel Bairey Merz, MD, director oftheBarbra Streisand Women's Heart Center, will participate in a cardiovascular health for women session, Where Are We Now: From WISE to CHEST PAIN Guidelines, Sunday, April 7, 12:45-12:52 p.m. EDT.

Natalie Bello, MD, MPH, director of Hypertension Research, will present Whats Sex Got to Do With It? Addressing Hypertension in Women, Monday, April 8, 12:45-1 p.m. EDT.

Joseph Ebinger, MD, associate professor of Cardiology, will present Bringing Hypertension Care to the People: Strategies to Address Disparities Among Racial/Ethnic Populations, Monday, April 8, 1:15-1:30 p.m. EDT.

Martha Gulati, MD, director of Preventive Cardiology and the Anita Dann Friedman Chair in Women's Cardiovascular Medicine and Research, will co-chair the session Don't Stop Me Now: Achieving Cardiovascular Health for Women, Sunday, April 7, 12:15-1:30 p.m. EDT.

Aakriti Gupta, MD, assistant professor of Cardiology, will participate in anetworking reception at ACC.24 that will bring together participants in the2025 Clinical Trials Research (CTR) program. Gupta is one of 28 structural heart cardiologists and surgeons selected for CTRs new Project REACH.

Raj Makkar, MD, associate director of the Smidt Heart Institute and vice president of Cardiovascular Innovation and Intervention at Cedars-Sinai,will co-chair the session Flipping the Script: Aortic Stenosis Management in the Modern Era, Saturday, April 6, 12-1:15 p.m. EDT. Makkar also will participate in the symposium Valve Repair and Replacement in Younger AdultsPercutaneous Versus Surgical Options, Saturday, April 6, 2:05-2:11 p.m. EDT.

David Ouyang, MD,assistant professor of Cardiology, will lead several discussions about the clinical applications of artificial intelligence, including Controversies in Medical AI, Saturday, April 6, 11:20 a.m.-12 p.m. EDT; Picturing the Future: Exploring the Use of AI in Cardiac Imaging, Saturday, April 6, 1:45-1:55 p.m. EDT; and Implementing AI Tools in Clinical Practice, Sunday, April 7, 2:10-2:20 p.m. EDT.

For more information: https://www.cedars-sinai.org/programs/heart.html

Find more ACC24 conference coverage here

Excerpt from:

ACC.24: Smidt Heart Institute Experts to Share Research Findings, Clinical Knowledge - Diagnostic and Interventional Cardiology

Cardiology

Cardiovascular Research Foundation, CRF, Introduces New York Valves: The Structural Heart Summit – Diagnostic and Interventional Cardiology

April 7, 2024 medical

April 5, 2024 TheCardiovascular Research Foundation(CRF) has announcedNew York Valves: The Structural Heart Summit, the expanded next iteration of our renowned annual Transcatheter Valve Therapy (TVT) conference. Taking place June 5-7, 2024, at the Jacob K. Javits Convention Center, North in New York City, the new summit will be a world-class educational experience in the field of structural heart interventions.

New York Valves 2024 signifies an important milestone for our organization, saidJuan F. Granada, MD, President and Chief Executive Officer of CRFand New York Valves Program Director. For the first time, this meeting will provide a unique interactive environment for networking, collaboration, and education, including all members of the heart team. It offers practitioners an unprecedented opportunity to learn about the latest developments in each specific area of our field. Through real multi-specialty collaboration, this summit will not only advance our knowledge but also directly impact patient care worldwide."

For nearly two decades, CRFhas led the way in pioneering transcatheter therapies for structural heart disease at TVT. New York Valves marks the next iteration of this legacy, featuring three days of transformative research and techniques that will redefine the landscape of structural heart interventions. Its the premier gathering uniting interventional cardiologists, cardiac surgeons, clinical cardiologists, cardiac imagers, heart failure experts, and other members of the heart team under one roof. With a renewed emphasis on multidisciplinary collaboration, New York Valves offers attendees the opportunity to harness the collective expertise of all specialties to develop the most effective and personalized treatment strategies for patients with valvular and structural heart disease.

New York Valves 2024 is more than just a meeting; it's a multidisciplinary movement reshaping the landscape of cardiovascular care in patients with valvular and structural heart disease, saidMartin B. Leon, MD, Founder and Chairman Emeritus of CRFand New York Valves Program Director. From novel therapies to best clinical practices, this summit embodies the evolution of transcatheter and surgical interventions. Our goal is to unite specialists from every corner of cardiovascular care to extend the heart team, redefine innovations, and develop new standards for managing valve patients."

Transcatheter valve therapy has evolved from a novel treatment for the sickest patients to become the standard of care for many with aortic stenosis. The rapid adoption of transcatheter mitral and tricuspid therapies has also transformed the treatment landscape, expanding options for patients with structural heart disease.

New York Valves 2024 will showcase advanced techniques and evidence-based medicine through live-case demonstrations, hands-on training, lively debate, and the latest updates that contribute knowledge to the field. With a distinguished lineup of world-renowned experts, this comprehensive program is designed as a practical, case-based course that will delve into best practices, clinical decision-making, patient selection, and strategies for devices, imaging, procedures, and complications management. The summit will also feature the latest breakthroughs and research in the field providing attendees with an unparalleled opportunity to explore the newest techniques and technologies in structural heart interventions.

For more information:www.crf.org

Medicare drops AUC requirement for advanced imaging, ASNC celebrates – Cardiovascular Business

April 7, 2024 medical

Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com

Originally posted here:

Medicare drops AUC requirement for advanced imaging, ASNC celebrates - Cardiovascular Business

Cardiology

Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions – Yale School of Medicine

April 7, 2024 medical

The American College of Cardiology (ACC) is holding its annual Scientific Meeting on April 6-8, 2024, where Yale faculty and trainees will present their latest clinical research.

Yales commitment to research is on full display at this years American College of Cardiology conference, where dozens of our faculty and trainees will share their contributions to science with our colleagues across the world, said Eric J. Velazquez, MD, Robert W. Berliner Professor of Medicine and chief of Yale Cardiovascular Medicine. Im extremely proud to lead a group of doctors and scientists who come to work each and every day thinking about how to advance the field of cardiovascular medicine all with the goal of providing patients with the best possible care.

Key presentations featuring Yale faculty and trainees include:

9:30 - 11:00 a.m. Session 1007: Outcome Prediction by Multimodality Imaging in Chronic CAD Moderated Poster Theater 07

9:30 - 11:00 a.m. Session 1008: Recognizing and Eliminated Disparities in CVD Moderated Poster Theater 08

9:45 - 10:30 a.m. Session 1201: Critical Care Cardiology 01 Hall B4-5

9:45 - 10:30 a.m. Session 1202: Innovation, Digital Health, and Technology 01 Hall B4-5

9:45 - 10:30 a.m. Session 1203: Vascular Medicine: Clinical Science 01 Hall B4-5

10:45 - 11:30 a.m. Session 1221: Complex Clinical Cases: FIT Valvular Heart Disease 02 Hall B4-5

10:45 - 11:30 a.m. Session 1232: Multimodality Imaging: Clinical Science 02 Hall B4-5

11:45 a.m. - 12:30 p.m. Session 1242: Spotlight on Special Topics: Cardio-OB 03 Hall B4-5

12:45 - 1:30 p.m. Session 1261: Innovation, Digital Health, and Technology 04 Hall B4-5

12:45 - 1:30 p.m. Session 1263: Vascular Medicine: Basic and Translational Science 04 Hall B4-5

1:30 - 3:00 p.m. Session 1032: Refining the Art of Implementation Science Moderated Poster Theater 08

1:45 - 2:30 p.m. Session 1282: Global Cardiovascular Health 05 Hall B4-5

1:45 - 2:30 p.m. Session 1283: Pulmonary Vascular Disease: Clinical and Population Science 05 Hall B4-5

1:45 - 2:30 p.m. Session 1288: Interventional and Structural: Endovascular Interventions 05 Hall B4-5

1:45 - 2:30 p.m. Session 1289: Interventional and Structural: Aortic Valve Interventions 05 Hall B4-5

2:45 - 3:30 p.m. Session 1305: Heart Failure and Cardiomyopathies: Clinical Science 06 Hall B4-5

2:45 - 3:30 p.m. Session 1307: Ischemic Heart Disease: Clinical Science 06 Hall B4-5

3:30 - 5:00 p.m. Session 1038: Back to the Future: Application of AI and ML in Heart Failure Moderated Poster Theater 02

3:30 - 5:00 p.m. Session 1045: Simulations and AI-Based Predictions Enhancing CV Care Moderated Poster Theater 09

3:45 - 4:30 p.m. Session 1321: Cardio-oncology 07 Hall B4-5

3:45 - 4:30 p.m. Session 1322: Vascular Medicine: Venous and Thromboembolic Disease 07 Hall B4-5

4:15 - 5:30 p.m. Session 632: Older and Wiser: Improving Health Across the Lifespan For Older Adults With Ischemic Heart Disease B401

8:00 - 9:15 a.m. Session 504: April Adventure: Top Interventional Trials of 2023 Thomas B. Murphy Ballroom 2

8:00 - 9:15 a.m. Session 1050: #GDMT Works: From Heart Failure to Heart Success Moderated Poster Theater 02

9:00 - 10:30 a.m. Session 1052: Peripheral Vascular Disease Moderated Poster Theater 04

9:15 - 10:00 a.m. Session 1340: Complex Clinical Cases: FIT Heart Failure 08 Hall B4-5

9:15 - 10:00 a.m. Session 1342: Vascular Medicine: Special Populations08 Hall B4-5

9:15 - 10:00 a.m. Session 1343: Heart Failure and Cardiomyopathies: Pharmacology 08 Hall B4-5

9:15 - 10:00 a.m. Session 1353: Prevention and Health Promotion: Diabetes and Cardiometabolic Disease 08 Hall B4-5

9:15 - 10:15 a.m. Session 2007: Heart Tank For the Cardiovascular Investigator: The Susan Smyth Memorial Tournament of Champions Engage Stage

9:45 - 11:00 a.m. Session 712: Joint Symposium of the American Heart Association and the American College of Cardiology B206

9:45 - 11:00 a.m. Session 505: April Adventure: The Great ECG Challenge Thomas B. Murphy Ballroom 2

9:45 - 11:00 a.m. Session 909: Highlighted Original Research: Heart Failure and Cardiomyopathies and the Year in Review B207

10:15 - 11:00 a.m. Session 1362: Training and Lifelong Learning 09 Hall B4-5

10:15 - 11:00 a.m. Session 1366: Ischemic Heart Disease: Clinical Science 09 Hall B4-5

10:15 - 11:00 a.m. Session 1371: Electrophysiology: Population Science 09 Hall B4-5

10:15 - 11:00 a.m. Session 1372: Prevention and Health Promotion: Diabetes and Cardiometabolic Disease 09 Hall B4-5

11:00 a.m. - 12:30 p.m. Session 1062: Neph Bomb: Decongestion in Heart Failure Moderated Poster Theater 02

11:00 a.m. - 12:30 p.m. Session 1064: Impact of Age on Interventional Cardiology Care Moderated Poster Theater 04

11:00 a.m. - 12:30 p.m. Session 1065: Vascular Vistas: Tailored Research For Special Populations Moderated Poster Theater 05

11:15 a.m. - 12:00 p.m. Session 1382: Critical Care Cardiology 10 Hall B4-5

11:15 a.m. - 12:00 p.m. Session 1384: Heart Failure and Cardiomyopathies: Population Science 10 Hall B4-5

11:15 a.m. - 12:00 p.m. Session 1385: Ischemic Heart Disease: Pharmacology 10 Hall B4-5

11:15 a.m. - 12:00 p.m. Session 1393: Prevention and Health Promotion: Population Science 10 Hall B4-5

12:15 - 1:00 p.m. Session 1401: Critical Care Cardiology 11 Hall B4-5

12:15 - 1:00 p.m. Session 1403: Vascular Medicine: Clinical Science 11 Hall B4-5

12:15 - 1:00 p.m. Session 1414: Prevention and Health Promotion: Lipids 11 Hall B4-5

1:00 - 2:30 p.m. Session 1075: Bulking Up Advances in Hypertrophic Cardiomyopathy Moderated Poster Theater 03

2:15 - 3:00 p.m. Session 1453: Prevention and Health Promotion: Diabetes and Cardiometabolic Disease 13 Hall B4-5

2:15 - 3:00 p.m. Session 1454: Prevention and Health Promotion: Lipids 13 Hall B4-5

3:15 - 4:00 p.m. Session 1461: Critical Care Cardiology 14 Hall B4-5

4:30 - 5:45 p.m. Session 709: Treating Arrhythmias in Athletes: When, Who and How? B312

8:30 - 9:45 a.m. Session 913: Highlighted Original Research: Interventional and Structural and the Year in Review B405

8:30 - 9:45 a.m. Session 914: Highlighted Original Research: Multimodality Imaging and the Year in Review B213

9:00 - 10:30 a.m. Session 1099: New Analyses From Heart Failure Clinical Trials Moderated Poster Theater 03

9:00 - 10:30 a.m. Session 1102: Not Just a Number: Ischemic Heart Disease in Older Populations Moderated Poster Theater 06

9:00 - 10:30 a.m. Session 1103: Quantitative Markers of Clinical Risk From Multimodality Imaging Moderated Poster Theater 07

9:00 - 10:30 a.m. Session 1104: Sex, Gender, Hormones, and the Heart Moderated Poster Theater 08

9:45 - 10:30 a.m. Session 1482: Vascular Medicine: Special Populations 15 Hall B4-5

9:45 - 10:30 a.m. Session 1487: Ischemic Heart Disease: Special Populations 15 Hall B4-5

9:45 - 10:30 a.m. Session 1489: Multimodality Imaging: MR 15 Hall B4-5

9:45 - 10:30 a.m. Session 1492: Prevention and Health Promotion: Lipids 15 Hall B4-5

10:45 - 11:30 a.m. Session 1501: Complex Clinical Cases: FIT Ischemic Heart Disease and Heart Failure 16 Hall B4-5

10:45 - 11:30 a.m. Session 1504: Heart Failure and Cardiomyopathies: Clinical Science 16 Hall B4-5

10:45 - 11:30 a.m. Session 1505: Ischemic Heart Disease: Population Science 16 Hall B4-5

10:45 - 11:30 a.m. Session 1508: Interventional and Structural: Coronary Interventions 16 Hall B4-5

11:00 a.m. - 12:15 p.m. Session 734: Finding Balance: Wellness in the CHD Clinician B308

11:00 a.m. - 12:30 p.m. Session 1114: Trends in Ischemic Heart Disease Moderated Poster Theater 06

11:00 a.m. - 12:30 p.m. Session 1115: Imaging Science on the Verge of Clinical Translation Moderated Poster Theater 07

11:45 a.m. - 12:30 p.m. Session 1520: Complex Clinical Cases: MD/PhD 17 Hall B4-5

11:45 a.m. - 12:30 p.m. Session 1523: Vascular Medicine: Clinical Science 17 Hall B4-5

12:45 - 1:30 p.m. Session 1546: Ischemic Heart Disease: Special Populations 18 Hall B4-5

12:45 - 2:00 p.m. Session 742: 2024 Eugene Braunwald Keynote Thomas B. Murphy Ballroom 4

2:30 - 3:45 p.m. Session 759: Step-by-Step Management of Patients With AFIB and LAA Occlusion in 2024 B405

View original post here:

Yale Faculty Present Groundbreaking Clinical Research at the 2024 American College of Cardiology Scientific Sessions - Yale School of Medicine

Cardiology

Getting Too Little Sleep Linked to High Blood Pressure – Diagnostic and Interventional Cardiology

April 7, 2024 medical

April 1, 2024 Sleeping fewer than seven hours is associated with a higher risk of developing high blood pressure over time, according to a study to be presented during the April 6-8American College of Cardiologys Annual Scientific Session & Expo, ACC.24.

While the association between sleep patterns and high blood pressure has been reported, evidence about the nature of this relationship has been inconsistent, according to researchers. The current analysis pools data from 16 studies conducted between January 2000 and May 2023, evaluating hypertension incidence in 1,044,035 people from six countries who did not have a prior history of high blood pressure over a median follow-up of five years (follow-up ranged from 2.4 to 18 years). Short sleep duration was significantly associated with a higher risk of developing hypertension after adjusting for demographic and cardiovascular risk factors, including age, sex, education, BMI, blood pressure, smoking status etc. Furthermore, the association was found to be even stronger for those getting less than five hours of sleep.

Based on the most updated data, the less you sleepthat is less than seven hours a daythe more likely you will develop high blood pressure in the future, said Kaveh Hosseini, MD, assistant professor of cardiology at the Tehran Heart Center in Iran and principal investigator of the study. In a news release summarizing the study, Hosseini added, We saw a trend between longer sleep durations and a greater occurrence of high blood pressure, but it was not statistically significant. Getting seven to eight hours of sleep, as is recommended by sleep experts, may be the best for your heart too.

The study found that sleeping less than seven hours was associated with a 7% increased risk of developing high blood pressure, which spiked to 11% when reported sleep duration was less than five hours. By comparison, diabetes and smoking are known to heighten ones risk of hypertension by at least 20%, Hosseini said.

While the study did not look at why this might be the case, Hosseini said that disrupted sleep could be to blame. For example, he said lifestyle habits or comorbid conditions such as overeating, alcohol use, nightshift work, certain medication use, anxiety, depression, sleep apnea or other sleep disorders may be factors.

Researchers were surprised there were no age-based differences in the association between sleep duration and hypertension given that sleep patterns tend to shift with age. The age of the participants ranged from 35.4 years to 60.9 years and more than half (61%) were female. When compared with men, females who reported less than seven hours of sleep had a 7% greater risk of developing high blood pressure.

Getting too little sleep appears to be riskier in females, Hosseini said. The difference is statistically significant, though we are not sure its clinically significant and should be further studied. What we do see is that lack of good sleep patterns may increase the risk of high blood pressure, which we know can set the stage for heart disease and stroke.

It's important for people to talk with their health care team about their sleep patterns, especially if they have disrupted sleep that might be due to obstructive sleep apnea. Sleep apnea has been tied to higher rates of high blood pressure, stroke and coronary artery disease.

This study has several limitations, including that sleep duration was based on self-reported questionnaires, so changes in sleep duration over the follow-up period were not assessed. Moreover, there were variations in how short sleep duration was defined between the studies (fewer than five or six hours).

Further research is required to evaluate the association between sleep duration and high blood pressure using more accurate methods like polysomnography, a method for evaluating sleep quality more precisely, Hosseini said. Moreover, the variations in reference sleep duration underline the need for standardized definition in sleep research to enhance the comparability and generalizability of findings across diverse studies.

Aayushi Sood, MD, lead author and medical resident at The Wright Center for Graduate Medical Education, will present the study, Sleep Duration and Hypertension Incidence: Systematic Review and Meta-Analysis, on Sunday, April 7 at 9:15 a.m. / 13:15 UTC in Hall B4-5.

ACC.24 will take place April 6-8, 2024, in Atlanta, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention.

For more information: http://www.acc.org

Find more ACC24 conference coverage here

See original here:

Getting Too Little Sleep Linked to High Blood Pressure - Diagnostic and Interventional Cardiology

Cardiology

What’s Going to Be Hot at ACC 2024 – TCTMD

April 7, 2024 medical

Later this week, the American College of Cardiology (ACC) 2024 Scientific Session celebrates its 75th anniversary by heading back to Atlanta for the first time since 2010, with the plans to return in 2021 dashed by the COVID-19 pandemic. In this years lineup are some eagerly awaited cardiovascular trials in the drug and device space, but also some less traditional approaches assessing game-based and financial incentives, spirituality, and unique population approaches.

According to Douglas Drachman, MD (Massachusetts General Hospital, Boston), the scientific sessions chair, 2024 will be a blockbuster of a year for the meeting, which received 1,100 more abstracts than last year and the most its received in two decades, with submissions coming from 79 countries worldwide. There was truly global input into this meeting and certainly we hope for global impact, Drachman told a media telebriefing last week.

Late-Breaking Lineup

There will be a total of five late-breaking clinical trial (LBCT) sessions spread over the 3-day meeting. LBCT I, on Saturday, showcases just three trials: RELIEVE-HF, EMPACT-MI, and AEGIS II. This last trial, we already know from top-line results, came up empty-handed and in doing so delivered what might be a mortal blow to the HDL-raising hypothesis.

RELIEVE-HF, by contrast, is exploring newer terrain. This the second-ever randomized trial of an atrial shunt to relieve pulmonary pressure in heart failure: early positive signals reported 2 years ago raised some hopes that this trial might yield better results than REDUCE LAP-HF II, where a different atrial shunt device proved no better than a sham procedure for relieving pulmonary wedge pressures.

From my standpoint, Im hopeful that this allows us to advance the care of people who are still refractory, said Katie Berlacher, MD (University of Pittsburgh, PA), who serves as the meetings vice chair and co-moderated the briefing. There are many patients who we have, both with reduced and preserved ejection fraction, that despite many of our really good medical therapies, they either can't be on more because they don't tolerate more, or they're on the most and they are still having heart failure [symptoms]. So I'm incredibly curious about a structural change to the heart that then treats this.

Rounding out LBCT I is EMPACT-MI, testing empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) prescription immediately after acute MI to reduce subsequent MACE over usual care. Here, too, ACC attendees will be thinking of a predecessor: DAPA-MI, presented at last years American Heart Association meeting, which tested dapagliflozin (Farxiga; AstraZeneca) in acute MI and also came up empty-handed. Notably, however, DAPA-MI specifical excluded patients with diabetes, whereas EMPACT-MI did not.

Sunday morning features two late-breaking sessions. LBCT II, at 8 AM, features a mix of lipid-lowering trials, the phase II KARDIA-2 hypertension trial testing zilebesiran (Alnylam), and a novel approach using gamification, financial incentives, or both to induce patients at risk of adverse CV events to be more physically active.

LBCT III, at 11 AM, is dominated by MI and ACS trials, the most hotly anticipated being DANGER-SHOCK testing the Impella percutaneous transvalvular micro-axial flow pump (Abiomed) in patients presenting with acute MI complicated by cardiogenic shock. As previously reported by TCTMD, this trial has faced uphill battles enrolling and randomizing the sickest of patients, leading to a steady stream of imperfect, observational studies to try to fill the knowledge gap.

Other LBCT III trials also will likely make headlines. TACT2 is revisiting the enticing idea that chelation might help post-MI in patients with diabetes. REDUCE-AMI is tackling the long-running question of whether long-term beta-blockers are helpful after MI in patients with preserved ejection fraction, particularly in the current era of guideline-directed medical therapy. Lastly, the ULTIMATE DAPT trial is the latest trial to try to cut down on post-PCI antiplatelet therapy regimens, this time with a strategy of just 1-month of ticagrelor monotherapy after ACS.

A lone structural heart disease trial appears in that session: the SMART trial is comparing a balloon-expandable and a self-expanding TAVI valve in patients with small aortic annuli.

Cardiomyopathies get the spotlight Monday morning. LBCT IV features two new agents and one old, in this space. ARISE-HF tested a selective aldose reductase inhibitor (at-001; Applied Therapeutics) for the treatment of diabetic cardiomyopathy. IMPROVE-HCM examined ninerafaxstat (Imbria Pharmaceuticals), a novel cardiac mitotrope, in patients with symptomatic nonobstructive hypertrophic cardiomyopathy. PROACT, however, features an old drug, the ACE inhibitor enalapril, for the possibility of preventing anthracycline-induced cardiotoxicity in breast cancer and lymphoma patients. The last two trials in LBCT IV are a study of tranexamic acid to prevent seizures after cardiac surgery and TACTiC, testing a technology-assisted means of administering nonprescription rosuvastatin.

The last late-breaking session of ACC 2024 delivers an interventional cardiology wallop. LBCT V includes ORBITA-COSMIC, a placebo-procedure-controlled trial of a coronary sinus reducer for refractory angina; DEDICATE-DZHK6, pitting surgery against TAVI in low- and intermediate-risk patients; the Target BP I trial of renal denervation, an IVUS versus angiography to guide drug-coated balloon therapy in femoropopliteal artery disease; and preventive PCI versus medical therapy in patients with unstable coronary plaques. This last, said Drachman during the ACC press briefing, is sort of the Holy Grail of cardiologypreventing a future heart attack[and] I hope this trial will give more insights.

More Science

Each of the late breakers get a second look in deep-dive sessions scheduled later in the day each day. There are also three featured clinical research sessions, one per day, showcasing updates from recent trials or novel registry analyses.

Some outside-the-box studies have been grouped under the umbrella of Clinical and Investigative Horizons on Saturday and include a registry-based, decentralized trial addressing ways of providing more equitable cardiovascular care, a study of CVD risk factors among National Football League players and families, an implementation science study aimed at increasing heart failure therapies among members of the Navajo Nation, and a study gauging the effects of spirituality on blood pressure.

It's not all trials and science, of course, as the meetings CV Team Lead Kimberly Guibone, DNP (Beth Israel Deaconess Medical Center, Boston, MA), explained to the media. There are dedicated sessions focused on business of medicine concerns for healthcare professionals, 11 game show-style sessions complete with quizzes, lights, and buzzers, andby popular demandthe puppies are back for stressed out conference attendees to get their hands on.

For more on whats to come at ACC 2024, check out the latest Rox Heart Radio. The TCTMD team will be on-site in Atlanta. Please reach out with tips, complaints, and comments: we hope to see you there.

What's Going to Be Hot at ACC 2024 - TCTMD